Robert T. Abraham
Directeur/Membre du Conseil chez Apertor Pharmaceuticals, Inc.
Profil
Robert T.
Abraham is currently the Associate Director at Duke Comprehensive Cancer Center and the Director at Apertor Pharmaceuticals, Inc. He was previously the Director at Allogene Therapeutics, Inc., SVP and Group Head-Oncology Research & Development at Pfizer Inc., Professor at Sanford Burnham Prebys Medical Discovery Institute and Duke University Medical Center, and Chief Scientific Officer at Vividion Therapeutics, Inc. Abraham holds a doctorate from the University of Pittsburgh and an undergraduate degree from Bucknell University.
Postes actifs de Robert T. Abraham
| Sociétés | Poste | Début |
|---|---|---|
Duke Comprehensive Cancer Center
 Duke Comprehensive Cancer Center Duke Comprehensive Cancer Center develops outpatient bone-marrow transplantation program. The company is headquartered in Durham, NC. | Corporate Officer/Principal | - |
Apertor Pharmaceuticals, Inc.
 Apertor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Apertor Pharmaceuticals, Inc. manufactures pharmaceutical products. | Directeur/Membre du Conseil | 01/11/2020 |
Anciens postes connus de Robert T. Abraham
| Sociétés | Poste | Fin |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | 01/12/2019 |
Sanford Burnham Prebys Medical Discovery Institute
 Sanford Burnham Prebys Medical Discovery Institute Medical/Nursing ServicesHealth Services Sanford Burnham Prebys Medical Discovery Institute conducts and translates biological research programs. The firm offers tumor initiation and maintenance, cancer metabolism and signaling network, tumor microenvironment and cancer immunology, degenerative disease, development/aging/regeneration, immunity and pathogenesis, human genetic, cardiovascular metabolism, integrative metabolism, metabolism genomic control, bioinformatics and structural biology programs. The company was founded by William Fishman and Lillian Fishman in 1976 and is headquartered in La Jolla, CA. | Corporate Officer/Principal | 01/06/2005 |
| ALLOGENE THERAPEUTICS, INC. | Directeur/Membre du Conseil | - |
| Duke University Medical Center | Corporate Officer/Principal | - |
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | - |
Formation de Robert T. Abraham
| University of Pittsburgh | Doctorate Degree |
| Bucknell University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| ALLOGENE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Sanford Burnham Prebys Medical Discovery Institute
Sanford Burnham Prebys Medical Discovery Institute Medical/Nursing ServicesHealth Services Sanford Burnham Prebys Medical Discovery Institute conducts and translates biological research programs. The firm offers tumor initiation and maintenance, cancer metabolism and signaling network, tumor microenvironment and cancer immunology, degenerative disease, development/aging/regeneration, immunity and pathogenesis, human genetic, cardiovascular metabolism, integrative metabolism, metabolism genomic control, bioinformatics and structural biology programs. The company was founded by William Fishman and Lillian Fishman in 1976 and is headquartered in La Jolla, CA. | Health Services |
Duke Comprehensive Cancer Center
Duke Comprehensive Cancer Center Duke Comprehensive Cancer Center develops outpatient bone-marrow transplantation program. The company is headquartered in Durham, NC. | |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Commercial Services |
Apertor Pharmaceuticals, Inc.
Apertor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Apertor Pharmaceuticals, Inc. manufactures pharmaceutical products. | Health Technology |